SECsense Logo

Portage Biotech Inc. Unveils Cyncado Therapeutics™: A Bold New Chapter

$PRTG
Form 6-K
Filed on: 2025-01-06
Source
Portage Biotech Inc. Unveils Cyncado Therapeutics™: A Bold New Chapter

Here are the key insights extracted from the financial report section provided:

  1. Filing Type and Date:
  • This document is a Form 6-K, which is typically used by foreign companies to report significant events to the SEC.
  • The report is dated January 6, 2025.
  1. Company Information:
  • The registrant is Portage Biotech Inc..
  • The company is incorporated in the British Virgin Islands, with its principal executive office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands.
  1. Commission File Number:
  • The SEC Commission File Number for Portage Biotech Inc. is 001-40086.
  1. Annual Reports:
  • The company indicated it files annual reports under Form 20-F.
  1. Significant Corporate Announcement:
  • On January 6, 2025, Portage Biotech Inc. issued a press release about the re-launch of its wholly-owned subsidiary as an independently managed entity named Cyncado Therapeutics™, focusing on developing adenosine receptor antagonists.
  • Peter Molloy has been appointed as the Chief Executive Officer of Cyncado Therapeutics.
  1. Incorporation by Reference:
  • The report states that this Form 6-K is incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc.
  1. Exhibit:
  • The press release mentioned is filed as Exhibit 99.1, providing further details about the subsidiary's focus and leadership.
  1. Signatory:
  • The report is signed by Andrea Park, who is the Chief Financial Officer of Portage Biotech Inc.

This information highlights significant corporate restructuring and leadership changes within Portage Biotech Inc., which may impact investor perceptions and market performance.